Novo is looking to succeed semaglutide with CagriSema, an injectable weight loss therapy that, like amycretin, targets both GLP-1 and amylin
Medicine is moving toward bio-optimization and performance medicine. And peptides are increasingly part of that conversation, largely because theyre becoming more accessible and of greater public interest
Bojsen-Mller Kirstine, N
While results may vary, LifeMD patients can expect to lose up to 20% of their body weight with GLP-1 treatment
On a final note, preclinical models are combined to reflect the responses in animals, although animals cannot be diagnosed with an addiction, so this is a limitation associated with preclinical studies
Suggested Use: As a dietary supplement for adults, take one (1) vegetable capsule up to two times daily, between meals or as directed by a healthcare practitioner